Clinical characteristics and prognosis of immunoglobulin D myeloma in the novel agent era

  • Lei Chen
  • Fengjuan Fan
  • Jun Deng
  • Jian Xu
  • Aoshuang Xu
  • Chunyan SunEmail author
  • Yu HuEmail author
Original Article


Immunoglobulin D (IgD) myeloma is a rare subtype that used to lead to a poor outcome. To investigate the current clinical features, cytogenetic changes and survival of patients with IgD myeloma under novel treatments, we analysed 47 patients with IgD myeloma, 31 men and 16 women, with a median age of 54.5 years. We found that IgD myeloma was associated with higher frequencies of anaemia, renal failure, and hypercalcemia and higher levels of serum LDH compared with non-IgD myeloma. More than 90% of patients with IgD myeloma had at least one cytogenetic abnormality demonstrated by fluorescence in situ hybridisation (FISH). IGH translocations were the most common abnormalities, which were mainly caused by t(11;14). Moreover, 36.2% of patients were at the Revised International Staging System (RISS) stage III when diagnosed. Those patients had significantly shorter PFS and OS compared with patients at RISS stages I and II. In conclusion, IgD myeloma has specific clinical characteristics. The RISS grade was shown to be a simple and effective method to predict the prognosis of patients with IgD myeloma.


Multiple myeloma Immunoglobulin D Revised international staging system Cytogenetic Prognosis 



This study was funded by the National Natural Science Foundation of China under grant no. 81272625 and no. 81670197 for Chunyan Sun.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

This article does not contain any studies with human participants or animals performed by any of the authors.


  1. 1.
    Jancelewicz Z, Takatsuki K, Sugai S, Pruzanski W (1975) IgD multiple myeloma: review of 133 cases. Arch Intern Med 135:87–93. CrossRefPubMedGoogle Scholar
  2. 2.
    Shimamoto Y, Anami Y, Yamaguchi M (1991) A new risk grouping for IgD myeloma based on analysis of 165 Japanese patients. Eur J Haematol 47:262–267. CrossRefPubMedGoogle Scholar
  3. 3.
    Bladé J, Lust JA, Kyle RA (1994) Immunoglobulin D multiple myeloma: presenting features, response to therapy, and survival in a series of 53 cases. J Clin Oncol 12:2398–2404. CrossRefPubMedGoogle Scholar
  4. 4.
    Kim MK, Suh C, Lee DH, Min CK, Kim SJ, Kim K, Moon JH, Yoon SS, Lee GW, Kang HJ, Kim SH, Choi CW, Eom HS, Kwak JY, Kim HJ, Mun YC, Bang SM, Lee K, Shin HJ, Lee JH, Korean Multiple Myeloma Working Party (2011) Immunoglobulin D multiple myeloma: response to therapy, survival, and prognostic factors in 75 patients. Ann Oncol 22:411–416. CrossRefPubMedGoogle Scholar
  5. 5.
    Gertz MA, Buadi FK, Hayman SR, Dingli D, Dispenzieri A, Greipp PR, Kumar SK, Lacy MQ, Lust JA, Leung N, Rajkumar SV, Russell SJ, Zeldenrust SR, Mikhael JR, Roy V, Kyle RA (2012) Immunoglobulin D amyloidosis: a distinct entity. Blood 119:44–48. CrossRefPubMedGoogle Scholar
  6. 6.
    Pisani F, Petrucci MT, Giannarelli D, Bongarzoni V, Montanaro M, de Stefano V, la Verde G, Gentilini F, Levi A, Za T, Moscetti A, Annino L, Petti MC, the Multiple Myeloma GIMEMA-Latium Region Working Group, Italy (2012) IgD multiple myeloma a descriptive report of 17 cases: survival and response to therapy. J Exp Clin Cancer Res 31:17. CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, Spicka I, Petrucci MT, Palumbo A, Samoilova OS, Dmoszynska A, Abdulkadyrov KM, Schots R, Jiang B, Mateos MV, Anderson KC, Esseltine DL, Liu K, Cakana A, van de Velde H, Richardson PG, VISTA Trial Investigators (2008) Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 359:906–917. CrossRefPubMedGoogle Scholar
  8. 8.
    Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Zeldenrust SR, Dingli D, Russell SJ, Lust JA, Greipp PR, Kyle RA, Gertz MA (2008) Improved survival in multiple myeloma and the impact of novel therapies. Blood 111:2516–2520. CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Majithia N, Vincent Rajkumar S, Lacy MQ, Buadi FK, Dispenzieri A, Gertz MA, Hayman SR, Dingli D, Kapoor P, Hwa L, Lust JA, Russell SJ, Go RS, Kyle RA, Kumar SK (2015) Outcomes of primary refractory multiple myeloma and the impact of novel therapies. Am J Hematol 90:981–985. CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Kumar SK, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Pandey S, Kapoor P, Dingli D, Hayman SR, Leung N, Lust J, McCurdy A, Russell SJ, Zeldenrust SR, Kyle RA, Rajkumar SV (2014) Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia 28:1122–1128. CrossRefPubMedGoogle Scholar
  11. 11.
    Benboubker L, Dimopoulos MA, Dispenzieri A, Catalano J, Belch AR, Cavo M, Pinto A, Weisel K, Ludwig H, Bahlis N, Banos A, Tiab M, Delforge M, Cavenagh J, Geraldes C, Lee JJ, Chen C, Oriol A, de la Rubia J, Qiu L, White DJ, Binder D, Anderson K, Fermand JP, Moreau P, Attal M, Knight R, Chen G, van Oostendorp J, Jacques C, Ervin-Haynes A, Avet-Loiseau H, Hulin C, Facon T, FIRST Trial Team (2014) Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. N Engl J Med 371:906–917. CrossRefPubMedGoogle Scholar
  12. 12.
    Fonseca R, Barlogie B, Bataille R, Bastard C, Bergsagel PL, Chesi M, Davies FE, Drach J, Greipp PR, Kirsch IR, Kuehl WM, Hernandez JM, Minvielle S, Pilarski LM, Shaughnessy JD Jr, Stewart AK, Avet-Loiseau H (2004) Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res 64:1546–1558CrossRefGoogle Scholar
  13. 13.
    Stewart AK, Fonseca R (2005) Prognostic and therapeutic significance of myeloma genetics and gene expression profiling. J Clin Oncol 23:6339–6344CrossRefGoogle Scholar
  14. 14.
    Avet-Loiseau H, Leleu X, Roussel M, Moreau P, Guerin-Charbonnel C, Caillot D, Marit G, Benboubker L, Voillat L, Mathiot C, Kolb B, Macro M, Campion L, Wetterwald M, Stoppa AM, Hulin C, Facon T, Attal M, Minvielle S, Harousseau JL (2010) Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p). J Clin Oncol 28:4630–4634. CrossRefPubMedGoogle Scholar
  15. 15.
    Dispenzieri A, Rajkumar SV, Gertz MA, Lacy MQ, Kyle RA, Greipp PR, Witzig TE, Lust JA, Russell SJ, Hayman SR, Kumar S, Zeldenrust SR, Fonseca R, Bergsagel PL, Reeder CB, Stewart AK, Roy V, Dalton RJ (2007) Treatment of newly diagnosed multiple myeloma based on Mayo stratification of myeloma and risk-adapted therapy (mSMART): consensus statement. Mayo Clin Proc 82:323–341CrossRefGoogle Scholar
  16. 16.
    Chim CS, Sim J, Tam S, Tse E, Lie AKW, Kwong YL (2015) LDH is an adverse prognostic factor independent of ISS in transplant-eligible myeloma patients receiving bortezomib-based induction regimens. Eur J Haematol 94:330–335. CrossRefPubMedGoogle Scholar
  17. 17.
    Moreau P, Cavo M, Sonneveld P, Rosinol L, Attal M, Pezzi A, Goldschmidt H, Lahuerta JJ, Marit G, Palumbo A, van der Holt B, Bladé J, Petrucci MT, Neben K, san Miguel J, Patriarca F, Lokhorst H, Zamagni E, Hulin C, Gutierrez N, Facon T, Caillot D, Benboubker L, Harousseau JL, Leleu X, Avet-Loiseau H, Mary JY (2014) Combination of international scoring system 3, high lactate dehydrogenase, and t(4;14) and/or del(17p) identifies patients with multiple myeloma (MM) treated with front-line autologous stem-cell transplantation at high risk of early MM progression-related. J Clin Oncol 32:2173–2180. CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, Richardson P, Caltagirone S, Lahuerta JJ, Facon T, Bringhen S, Gay F, Attal M, Passera R, Spencer A, Offidani M, Kumar S, Musto P, Lonial S, Petrucci MT, Orlowski RZ, Zamagni E, Morgan G, Dimopoulos MA, Durie BGM, Anderson KC, Sonneveld P, San Miguel J, Cavo M, Rajkumar SV, Moreau P (2015) Revised international staging system for multiple myeloma: a report from international myeloma working group. J Clin Oncol 33:2863–2869. CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Palumbo A, Rajkumar SV, San Miguel JF, Larocca A, Niesvizky R, Morgan G, Landgren O, Hajek R, Einsele H, Anderson KC, Dimopoulos MA, Richardson PG, Cavo M, Spencer A, Stewart AK, Shimizu K, Lonial S, Sonneveld P, Durie BGM, Moreau P, Orlowski RZ (2014) International myeloma working group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation. J Clin Oncol 32:587–600. CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Bladé J, Kyle RA (1999) Nonsecretory myeloma, immunoglobulin D myeloma, and plasma cell leukemia. Hematol Oncol Clin North Am 13:1259–1272CrossRefGoogle Scholar
  21. 21.
    Reece DE, Vesole DH, Shrestha S, Zhang MJ, Pérez WS, Dispenzieri A, Milone GA, Abidi M, Atkins H, Bashey A, Bredeson CN, Boza WB, Freytes CO, Gale RP, Gajewski JL, Gibson J, Hale GA, Kumar S, Kyle RA, Lazarus HM, McCarthy PL, Pavlovsky S, Roy V, Weisdorf DJ, Wiernik PH, Hari PN (2010) Outcome of patients with IgD and IgM multiple myeloma undergoing autologous hematopoietic stem cell transplantation: a retrospective CIBMTR study. Clin Lymphoma Myeloma Leuk 10:458–463. CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Lu J, Lu J, Chen W, Wang J, Huo Y, Hou J, Huang X (2016) More frequent IgD and reduced CD200 expression in Chinese patients younger than 50 years old with multiple myeloma: a multicenter analysis. Drug Des Devel Ther 10:3673–3679. CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Wang GR, Sun WJ, Chen WM, Huang ZX, Zhang JJ, An N, Shen M, Li X (2016) Immunoglobulin D multiple myeloma: disease profile, therapeutic response, and survival. Acta Haematol 136:140–146. CrossRefPubMedGoogle Scholar
  24. 24.
    Zagouri F, Kastritis E, Symeonidis AS, Giannakoulas N, Katodritou E, Delimpasi S, Repousis P, Terpos E, Dimopoulos MA, The Greek Myeloma Study Group (2014) Immunoglobulin D myeloma: clinical features and outcome in the era of novel agents. Eur J Haematol 92:308–312. CrossRefPubMedGoogle Scholar
  25. 25.
    An G, Xu Y, Shi L, Zou D, Deng S, Sui W, Xie Z, Hao M, Chang H, Qiu L (2013) T(11;14) multiple myeloma: a subtype associated with distinct immunological features, immunophenotypic characteristics but divergent outcome. Leuk Res 37:1251–1257. CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Institute of Hematology, Union Hospital, Tongji Medical CollegeHuazhong University of Science and TechnologyWuhanChina

Personalised recommendations